Aura Biosciences Executives Buy $13.1M in Stock Amid Recent Surge

Aura Biosciences, Inc. [AURA] announced today that Senior Vice President, Finance Elazzouzi Amy has executed the following transactions: * Purchased 2,554 shares at a price of $5.07 per share on August 18, 2025. * Purchased 1,094 shares at a price of $5.48 per share on August 18, 2025. * Purchased 547 shares at a price of $5.48 per share on August 18, 2025. * Purchased 547 shares at a price of $5.21 per share on August 18, 2025. * Purchased 4,744 shares at a price of $2.74 per share on August 18, 2025. * Purchased 2,319 shares at a price of $4.25 per share on August 18, 2025. * Purchased 1,094 shares at a price of $3.16 per share on August 18, 2025. * Sold 7,722 shares at a price of $6.7 per share on August 18, 2025.

Aura Biosciences, Inc. (AURA), a clinical-stage biotechnology company focused on precision therapies for solid tumors, announced today that Senior Vice President, Finance Elazzouzi Amy has executed several significant share transactions. The transactions, which occurred on August 18, 2025, include both purchases and sales of AURA shares.

Elazzouzi Amy purchased a total of 11,295 shares at various prices, ranging from $2.74 to $5.48 per share. The breakdown of the purchases is as follows:
- 2,554 shares at $5.07 per share
- 1,094 shares at $5.48 per share
- 547 shares at $5.48 per share
- 547 shares at $5.21 per share
- 4,744 shares at $2.74 per share
- 2,319 shares at $4.25 per share
- 1,094 shares at $3.16 per share

Additionally, Elazzouzi Amy sold 7,722 shares at a price of $6.7 per share.

These transactions highlight the company's ongoing efforts to manage its shareholder base and potentially influence stock price dynamics. The purchase of shares at different prices indicates a strategic approach to acquiring shares at what may be perceived as undervalued levels. The sale of shares at a higher price suggests a potential exit strategy or a move to reduce exposure to the stock.

Aura Biosciences has been focusing on the development of bel-sar, a precision therapy for solid tumors, with ongoing clinical trials in early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). The company recently reported strong financial results and secured $75 million in equity financing, which is expected to fund operations into the first half of 2027 [2].

Investors should closely monitor Aura Biosciences' financial health and clinical progress to assess the potential impact of these transactions on the company's stock performance.

References:
[1] https://finance.yahoo.com/news/think-aura-biosciences-nasdaq-aura-100853522.html
[2] https://www.globenewswire.com/news-release/2025/08/13/3132426/0/en/Aura-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Business-Highlights.html